Yiling Pharmaceutical controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile6 entries
2022
Singapore authorities warn against treating COVID-19 with Lianhua Qingwen
Singapore’s health authorities stated that Lianhua Qingwen was not approved to prevent or treat COVID-19 and cautioned the public against relying on it for that purpose. The statement reflected regulatory concerns over…
2022
United States FDA issues import alert involving Lianhua Qingwen
The U.S. Food and Drug Administration listed an import alert covering certain unapproved or improperly labeled products marketed for COVID-19-related purposes, including Lianhua Qingwen. The action concerned U.S. regula…
2022
Regulatory controversy over Lianhua Qingwen COVID-19 claims
International regulators and health authorities challenged or restricted COVID-19-related interpretations and marketing of Lianhua Qingwen. Singapore stated that the product was not approved to prevent or treat COVID-19…
2022
Efficacy of Lianhua Qingwen and promotion for preventive use questioned; company issues public response
In April 2022, Yiling Pharmaceutical faced questions over the development timeline, efficacy, and preventive use of Lianhua Qingwen, and the company issued a statement explaining its research and trial evidence. The entry distinguishes approved indications from public misunderstanding of preventive use.
2022
Online claims of liver injury spark safety discussion; company denies them and explains research basis
In December 2022, online claims emerged that Lianhua Qingwen could cause liver injury, and Yiling Pharmaceutical denied them and provided research evidence. The entry preserves the controversy and the company's position without confirming the alleged causal link or asserting that all use is risk-free.
2021
Undisclosed relationship between Lianhua Qingwen study author and pharmaceutical executive sparks conflict-of-interest controversy
In 2021, Caixin reported that the corresponding author of a study on Lianhua Qingwen against COVID-19 was married to a pharmaceutical company director, and the paper did not declare the relevant conflict of interest, sparking controversy over the independence of the research. The challenge is not equivalent to a finding that the study data were falsified.